Genetic Regulation of Hepatic Glucagon Signaling in Metabolic Dysfunction

Abstract

Hepatic glucagon signaling is a central determinant of glucose, lipid, amino acid, and energy metabolism. In metabolic dysfunction, including obesity, insulin resistance, metabolic dysfunction-associated steatotic liver disease, and type 2 diabetes, the response to glucagon is altered by genetic variation, epigenetic remodeling, changes in receptor abundance, and defects in intracellular signal transduction. The hepatic glucagon receptor activates primarily G protein–coupled pathways involving adenylate cyclase, cyclic adenosine monophosphate, protein kinase A, exchange protein directly activated by cAMP, and downstream transcriptional regulators. Genetic regulation of these pathways influences fasting glucose production, ketogenesis, ureagenesis, lipid oxidation, and susceptibility to hepatic steatosis. Variants in the glucagon receptor gene, signaling intermediates, transcription factors, and metabolic regulators may modify disease risk and therapeutic response. This review summarizes the disease burden, molecular pathophysiology, clinical manifestations, diagnostic considerations, current management, emerging therapies, and guideline-informed implications of genetically regulated hepatic glucagon signaling.

Introduction

Glucagon is secreted by pancreatic alpha cells in response to falling plasma glucose, increased amino acid availability, sympathetic stimulation, and selected hormonal signals. Its most important metabolic target is the liver, where it promotes glycogenolysis, gluconeogenesis, fatty acid oxidation, ketogenesis, and amino acid catabolism. In healthy physiology, glucagon counterbalances insulin and preserves glucose availability during fasting. In metabolic dysfunction, however, glucagon secretion and action become dysregulated. Hyperglucagonemia, inappropriate hepatic glucose production, and impaired coordination between insulin and glucagon contribute to fasting hyperglycemia and progressive metabolic disease.

Genetic regulation is relevant at several levels. Germline variants can affect glucagon receptor expression, ligand binding, G protein coupling, cAMP generation, phosphodiesterase activity, kinase signaling, and transcriptional responses. Epigenetic changes associated with obesity, inflammation, nutrient excess, and altered bile acid metabolism can further modify the activity of glucagon-responsive genes. Understanding these mechanisms is clinically important because individuals with similar levels of obesity or insulin resistance may develop markedly different patterns of steatosis, hyperglycemia, dyslipidemia, and hepatic fibrosis.

Epidemiology / Disease Burden

Metabolic dysfunction-associated steatotic liver disease is now among the most common chronic liver disorders worldwide and frequently coexists with obesity, type 2 diabetes, hypertension, and atherogenic dyslipidemia. The burden is driven by increasing adiposity, sedentary behavior, aging populations, and dietary patterns characterized by excess refined carbohydrates and energy-dense foods. A substantial proportion of affected individuals develop steatohepatitis, progressive fibrosis, cirrhosis, or hepatocellular carcinoma.

Abnormal glucagon biology is common across this spectrum. Some patients exhibit elevated fasting glucagon concentrations, impaired suppression after meals, or an exaggerated response to amino acids. The resulting hepatic glucose output can worsen glycemic control, while excessive glucagon signaling may increase hepatic fatty acid delivery and ketone production in susceptible states. Genetic background contributes to interindividual differences in disease severity. Variants influencing hepatocellular lipid handling, insulin signaling, glucagon receptor activity, or fibrogenic responses may modify the transition from simple steatosis to inflammatory and fibrotic disease.

Pathophysiology

The hepatic glucagon receptor is a class B G protein–coupled receptor encoded by the GCGR gene. Ligand binding activates heterotrimeric G proteins, particularly Gs, stimulating adenylate cyclase and increasing intracellular cAMP. cAMP activates protein kinase A and exchange protein directly activated by cAMP, which regulate metabolic enzymes and transcription factors. Protein kinase A phosphorylates glycogen phosphorylase and phosphorylase kinase, facilitating glycogen breakdown, while inhibiting glycogen synthase. It also promotes transcriptional programs involving cAMP response element-binding protein and coactivators such as CREB-regulated transcription coactivator 2.

During fasting, this pathway increases expression of phosphoenolpyruvate carboxykinase and glucose-6-phosphatase, thereby supporting gluconeogenesis. Glucagon also stimulates peroxisome proliferator-activated receptor alpha–dependent fatty acid oxidation and ketogenesis. In the urea cycle, glucagon enhances nitrogen disposal and helps the liver process amino acids released during fasting. These effects are beneficial when coordinated with insulin and nutritional status, but become maladaptive when glucagon signaling remains elevated during nutrient excess.

Genetic variation in GCGR may alter receptor density, cellular trafficking, ligand affinity, or coupling to downstream signaling proteins. Variants in ADCY genes, protein kinase A components, phosphodiesterases, and cAMP-responsive transcriptional regulators can influence signal intensity and duration. Genetic differences in FOXO1, PGC-1alpha, hepatocyte nuclear factors, and related gluconeogenic regulators may also determine how strongly the liver converts a glucagon signal into glucose production.

Metabolic dysfunction further modifies this network through insulin resistance, endoplasmic reticulum stress, mitochondrial impairment, inflammation, and altered nutrient sensing. In insulin-resistant liver, glucagon-driven gluconeogenesis is less effectively opposed by insulin. Conversely, chronic hyperinsulinemia may change receptor signaling and promote compensatory hyperglucagonemia. Epigenetic mechanisms, including DNA methylation, histone modification, and microRNA activity, can alter the expression of glucagon receptors and metabolic enzymes without changing the underlying DNA sequence.

Risk Factors

Major risk factors include central obesity, type 2 diabetes, prediabetes, dyslipidemia, hypertension, sleep-disordered breathing, physical inactivity, and diets rich in fructose, saturated fat, and ultra-processed foods. Menopause, older age, and genetic predisposition may increase the likelihood of progressive hepatic disease. A family history of diabetes, steatotic liver disease, premature cardiovascular disease, or unexplained cirrhosis should raise clinical suspicion of inherited susceptibility.

Genetic risk is not determined by a single variant. Polygenic effects involving lipid export, de novo lipogenesis, insulin signaling, inflammatory activation, and fibrogenesis are clinically more relevant than most isolated variants. Additional modifiers include alcohol exposure, certain medications, rapid weight loss, malnutrition, and coexisting viral or autoimmune liver disease. The interaction between genotype and environment is particularly important: a high-risk genotype may remain clinically silent in a metabolically favorable environment but become consequential with sustained energy surplus and insulin resistance.

Clinical Features

Patients may be asymptomatic, with abnormalities detected through routine aminotransferase testing or imaging. Others present with fatigue, right upper quadrant discomfort, hepatomegaly, or metabolic complications such as hyperglycemia and hypertriglyceridemia. Clinical progression is determined more by fibrosis than by steatosis alone. Advanced disease may produce thrombocytopenia, splenomegaly, portal hypertension, ascites, jaundice, encephalopathy, or hepatocellular carcinoma.

Disordered hepatic glucagon signaling commonly manifests as fasting hyperglycemia, increased postprandial glucose excursion, excessive ketogenesis during caloric restriction, and impaired metabolic flexibility. In patients with insulin deficiency or severe insulin resistance, increased glucagon action may contribute to ketosis and, in appropriate clinical settings, diabetic ketoacidosis. The phenotype varies according to genetic background, residual insulin secretion, nutritional state, renal function, and treatment exposure.

Diagnosis

Evaluation should establish the presence and severity of metabolic dysfunction while excluding alternative causes of liver injury. Initial testing generally includes glycated hemoglobin, fasting glucose, lipid profile, alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, bilirubin, albumin, platelet count, and assessment of renal function. Additional testing may be required for viral hepatitis, autoimmune liver disease, iron overload, Wilson disease, alpha-1 antitrypsin deficiency, or drug-induced injury.

Ultrasound, controlled attenuation parameter assessment, magnetic resonance imaging, and magnetic resonance elastography can quantify steatosis and estimate fibrosis. Noninvasive scores such as the fibrosis-4 index may help determine referral and follow-up needs, although age, inflammation, and comorbidities affect interpretation. Liver biopsy remains useful when the diagnosis is uncertain, competing disorders are suspected, or histologic staging will alter management.

Routine measurement of circulating glucagon is not currently recommended for most clinical settings because assays differ in specificity and preanalytical handling. Research evaluation may include dynamic hormone testing, metabolomic profiling, transcriptomics, and genomic analysis. Genetic testing should be considered selectively, particularly when there is unusually early disease, severe or atypical metabolic presentation, a strong family history, syndromic features, or suspected monogenic diabetes. Polygenic risk scores are not yet a substitute for conventional clinical assessment.

Treatment & Management

Management should address the full metabolic phenotype rather than glucagon signaling in isolation. Sustained weight reduction through individualized nutritional therapy, increased physical activity, and behavioral support can improve hepatic steatosis, insulin sensitivity, and abnormal hormone dynamics. Even moderate weight loss may reduce liver fat, while greater reductions are more likely to improve steatohepatitis and fibrosis. Resistance training and aerobic exercise are beneficial even when weight loss is modest.

Glycemic treatment should be selected according to cardiovascular, renal, hepatic, and weight-related priorities. Metformin remains useful for glycemic control but is not a specific antifibrotic therapy. Sodium-glucose cotransporter 2 inhibitors can improve glycemia, body weight, and cardiorenal outcomes in appropriate patients. Glucagon-like peptide-1 receptor agonists and related incretin-based therapies may reduce appetite, promote substantial weight loss, and improve metabolic liver disease. Pioglitazone can be considered in selected patients with type 2 diabetes and steatohepatitis after weighing weight gain, edema, fracture risk, and other contraindications.

Dyslipidemia should be treated aggressively, and statins are generally appropriate when indicated because cardiovascular risk is a major cause of death in metabolic liver disease. Alcohol intake should be assessed and minimized, hepatotoxic medications reviewed, and vaccination against relevant viral hepatitis considered. Patients with advanced fibrosis require structured surveillance for hepatocellular carcinoma and portal hypertension according to hepatology guidance.

Recent Advances / Emerging Therapies

Pharmacologic development has increasingly focused on restoring metabolic balance rather than simply blocking glucagon. Glucagon receptor antagonists can reduce hepatic glucose production, but clinical development has been limited by potential increases in liver fat, aminotransferases, plasma lipids, and compensatory alpha-cell hyperplasia. Partial antagonism, tissue-selective modulation, and biased receptor signaling are being investigated to preserve beneficial effects on energy expenditure and lipid oxidation while reducing excessive gluconeogenesis.

Dual and triple agonists combining glucagon activity with glucagon-like peptide-1 and, in some compounds, glucose-dependent insulinotropic polypeptide signaling may produce coordinated weight loss and improvements in glucose and liver fat. Their therapeutic window depends on balancing glucagon-mediated energy expenditure and lipid mobilization against hyperglycemia and gastrointestinal intolerance. Precision approaches may eventually use genetic and molecular profiles to identify patients most likely to benefit from receptor agonism, antagonism, or pathway-specific modulation.

Additional research areas include epigenetic therapies, RNA-based regulation of metabolic genes, liver-targeted delivery systems, microbiome-mediated modulation of bile acid and glucagon-like signaling, and computational integration of genomic, transcriptomic, and clinical data. Translation into routine care will require validated biomarkers, long-term safety data, and evidence that molecular improvements reduce fibrosis, cardiovascular events, and liver-related mortality.

Guideline Recommendations

Current clinical guidance supports risk-based evaluation of patients with metabolic risk factors and suspected steatotic liver disease. Primary care clinicians should identify obesity, diabetes, dyslipidemia, hypertension, and abnormal liver tests, then use noninvasive fibrosis assessment to guide monitoring or specialist referral. Patients with indeterminate or high fibrosis risk should undergo further elastography or hepatology evaluation.

Guidelines consistently recommend lifestyle intervention, gradual and durable weight loss, regular physical activity, optimization of diabetes and lipid therapy, and management of cardiovascular risk. No guideline currently recommends routine clinical genotyping of glucagon signaling genes for common metabolic dysfunction. Genetic testing should be directed by phenotype and family history, with pretest counseling and appropriate interpretation. Treatment decisions should not be based on a genetic variant without evidence that it changes prognosis or therapeutic response.

Conclusion

Genetic regulation of hepatic glucagon signaling provides an important framework for understanding why metabolic dysfunction produces heterogeneous patterns of hyperglycemia, steatosis, ketogenesis, and liver injury. Variants affecting the glucagon receptor and its cAMP-dependent network interact with insulin resistance, nutrient excess, inflammation, and epigenetic remodeling to determine hepatic metabolic behavior. At present, clinical care should emphasize comprehensive risk assessment, noninvasive fibrosis staging, weight management, evidence-based cardiometabolic treatment, and appropriate specialist referral. Future precision medicine strategies may integrate genomic and functional biomarkers to select glucagon pathway modulators more safely and effectively, but their value will depend on demonstrating durable improvements in hepatic, metabolic, and cardiovascular outcomes.